Recruiting NCT04799002
Topotecan and Melphalan for Retinoblastoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Topotecan, Melphalan.
- Who it may be relevant to
- Registry conditions: Retinoblastoma, Chemotherapy Effect. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Choice of Topotecan or Melphalan in Retinoblastoma Patients
Overview
The purpose of this study is to evaluate topotecan and melphalan for retinoblastoma patients.
Detailed description
To evaluate the effectiveness and complications of topotecan and melphalan for intraocular injection in retinoblastoma patients.
Interventions
- Drug Topotecan
Topotecan intraocular injection for chemotherapy in retinoblastoma - Drug Melphalan
Melphalan intraocular injection for chemotherapy in retinoblastoma
Primary outcome measures
- Eyeball-sparing rate [Time frame: 5 years after chemotherapy]
Secondary outcome measures (1)
- Side effects [Time frame: 5 years after chemotherapy]
Eligibility criteria
Inclusion criteria
- diagnosed as retinoblastoma
- receiving eyeball-sparing treatment
Exclusion criteria
- disease progression during follow-up
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Non-randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 1 center
- Sun Yat-sen University — Guangzhou
Identifiers
NCT: NCT04799002 · 202103